These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

550 related articles for article (PubMed ID: 24708575)

  • 1. Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial.
    Eskandary F; Bond G; Schwaiger E; Kikic Z; Winzer C; Wahrmann M; Marinova L; Haslacher H; Regele H; Oberbauer R; Böhmig GA
    Trials; 2014 Apr; 15():107. PubMed ID: 24708575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Late Antibody-Mediated Rejection in a Large Prospective Cross-Sectional Study of Kidney Allograft Recipients--Preliminary Results of the Screening Phase of the BORTEJECT Trial.
    Eskandary F; Bond G; Regele H; Kozakowski N; Kikić Z; Wahrmann M; Haslacher H; Oberbauer R; Ramassar V; Halloran P; Böhmig GA
    Clin Transpl; 2014; ():189-95. PubMed ID: 26281144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial.
    Eskandary F; Dürr M; Budde K; Doberer K; Reindl-Schwaighofer R; Waiser J; Wahrmann M; Regele H; Spittler A; Lachmann N; Firbas C; Mühlbacher J; Bond G; Halloran PF; Chong E; Jilma B; Böhmig GA
    Trials; 2019 Jan; 20(1):37. PubMed ID: 30635033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib for refractory acute antibody-mediated rejection in kidney transplant recipients: A single-centre case series.
    De Sousa-Amorim E; Revuelta I; Diekmann F; Cofan F; Lozano M; Cid J; Palou E; Sole M; Campistol JM; Oppenheimer F
    Nephrology (Carlton); 2016 Aug; 21(8):700-4. PubMed ID: 26492594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib for the treatment of chronic antibody-mediated kidney allograft rejection: a case report.
    Schwaiger E; Regele H; Wahrmann M; Werzowa J; Haidbauer B; Schmidt A; Böhmig GA
    Clin Transpl; 2010; ():391-6. PubMed ID: 21696056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection.
    Eskandary F; Regele H; Baumann L; Bond G; Kozakowski N; Wahrmann M; Hidalgo LG; Haslacher H; Kaltenecker CC; Aretin MB; Oberbauer R; Posch M; Staudenherz A; Handisurya A; Reeve J; Halloran PF; Böhmig GA
    J Am Soc Nephrol; 2018 Feb; 29(2):591-605. PubMed ID: 29242250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of bortezomib as a rescue treatment for acute antibody-mediated rejection: report of three cases and review of literature.
    Tzvetanov I; Spaggiari M; Joseph J; Jeon H; Thielke J; Oberholzer J; Benedetti E
    Transplant Proc; 2012 Dec; 44(10):2971-5. PubMed ID: 23195008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reducing Donor-specific Antibody During Acute Rejection Diminishes Long-term Renal Allograft Loss: Comparison of Early and Late Rejection.
    Lichvar AB; Tremblay S; Leino AD; Shields AR; Cardi MA; Abu Jawdeh BG; Govil A; Kremer J; Cuffy M; Paterno F; Diwan T; Brailey P; Girnita A; Alloway RR; Woodle ES
    Transplantation; 2020 Nov; 104(11):2403-2414. PubMed ID: 32000256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection.
    Walsh RC; Everly JJ; Brailey P; Rike AH; Arend LJ; Mogilishetty G; Govil A; Roy-Chaudhury P; Alloway RR; Woodle ES
    Transplantation; 2010 Feb; 89(3):277-84. PubMed ID: 20145517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Durable renal response after combination of bortezomib, corticosteroids, rituximab, and plasmapheresis for late antibody-mediated renal transplant rejection
.
    Ding Y; Francis J; Gautam A; Pelletier L; Sanchorawala V; Quillen K
    Clin Nephrol; 2018 Apr; 89(4):252-259. PubMed ID: 29208204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
    Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clazakizumab for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients: Phase 3 IMAGINE study rationale and design.
    Nickerson PW; Böhmig GA; Chadban S; Kumar D; Mannon RB; van Gelder T; Lee JC; Adler S; Chong E; Djamali A
    Trials; 2022 Dec; 23(1):1042. PubMed ID: 36550562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Banff Component Scoring-based Histologic Assessment of Bortezomib-based Antibody-mediated Rejection Therapy.
    Sadaka B; Ejaz NS; Shields AR; Cardi MA; Wadih G; Witte D; Abu Jawdeh BG; Alloway RR; Woodle ES
    Transplantation; 2015 Aug; 99(8):1691-9. PubMed ID: 25803498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib as an adjuvant to conventional therapy in the treatment of antibody mediated rejection (AMR): the full spectrum.
    Al Meshari K; Pall A; Elgamal H; Alzayer F; Altalhi M
    Clin Transpl; 2010; ():383-90. PubMed ID: 21696055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting alloantibody production with bortezomib: does it make more sense?
    Lee I; Constantinescu S; Gillespie A; Rao S; Silva P; Birkenbach M; Leech S; Karachristos A; Daller JA; Sifontis NM
    Clin Transpl; 2010; ():397-403. PubMed ID: 21696057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concurrent acute cellular rejection is an independent risk factor for renal allograft failure in patients with C4d-positive antibody-mediated rejection.
    Matignon M; Muthukumar T; Seshan SV; Suthanthiran M; Hartono C
    Transplantation; 2012 Sep; 94(6):603-11. PubMed ID: 22932115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Late antibody-mediated rejection in renal allografts: outcome after conventional and novel therapies.
    Gupta G; Abu Jawdeh BG; Racusen LC; Bhasin B; Arend LJ; Trollinger B; Kraus E; Rabb H; Zachary AA; Montgomery RA; Alachkar N
    Transplantation; 2014 Jun; 97(12):1240-6. PubMed ID: 24937198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteasome inhibition with bortezomib: an effective therapy for severe antibody mediated rejection after renal transplantation.
    Sureshkumar KK; Hussain SM; Marcus RJ; Ko TY; Khan AS; Tom K; Vivas CA; Parris G; Jasnosz KM; Thai NL
    Clin Nephrol; 2012 Mar; 77(3):246-53. PubMed ID: 22377258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients.
    Morrow WR; Frazier EA; Mahle WT; Harville TO; Pye SE; Knecht KR; Howard EL; Smith RN; Saylors RL; Garcia X; Jaquiss RD; Woodle ES
    Transplantation; 2012 Feb; 93(3):319-24. PubMed ID: 22179403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib alone fails to decrease donor specific anti-HLA antibodies: even after one year post-treatment.
    Sberro-Soussan R; Zuberl J; Suberbielle-Boissel C; Legendre C
    Clin Transpl; 2010; ():409-14. PubMed ID: 21696059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.